Anti-IL-5 and anti-IL-5 receptor therapy significantly improves quality of life and FEV1 values in patients with severe asthma.
- DOI
- 10.1186/s13223-025-00979-y
- Published
- 2025 Aug 13
- Container
- Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s13223-025-00979-y,
title = {Anti-IL-5 and anti-IL-5 receptor therapy significantly improves quality of life and FEV1 values in patients with severe asthma.},
author = {Alfaro AOV and Vargas HCG and Díaz JM and Pinto JA and Cambero DCG and Cuellar EH and Zapata JAP and Domínguez AEL and Zapata JP and Ponce-Campos SD},
year = {2025},
journal = {Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology},
doi = {10.1186/s13223-025-00979-y},
url = {https://doi.org/10.1186/s13223-025-00979-y}
}RIS
TY - JOUR TI - Anti-IL-5 and anti-IL-5 receptor therapy significantly improves quality of life and FEV1 values in patients with severe asthma. AU - Alfaro AOV AU - Vargas HCG AU - Díaz JM AU - Pinto JA AU - Cambero DCG AU - Cuellar EH AU - Zapata JAP AU - Domínguez AEL AU - Zapata JP AU - Ponce-Campos SD PY - 2025 JO - Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology DO - 10.1186/s13223-025-00979-y UR - https://doi.org/10.1186/s13223-025-00979-y ER -
APA
AOV, A., HCG, V., JM, D., JA, P., DCG, C., EH, C., JAP, Z., AEL, D., JP, Z., & SD, P. (2025). Anti-IL-5 and anti-IL-5 receptor therapy significantly improves quality of life and FEV1 values in patients with severe asthma.. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology. https://doi.org/10.1186/s13223-025-00979-y
Source records
- pubmed · retrieved 2026-11-10T16:52:59.582Z